Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 2/2011

01-04-2011 | Commentary

The role of receptor for advanced glycation endproducts (RAGE) in infection

Authors: Marieke AD van Zoelen, Ahmed Achouiti, Tom van der Poll

Published in: Critical Care | Issue 2/2011

Login to get access

Excerpt

During evolution, multicellular organisms have developed an impressive arsenal of defense and repair mechanisms to counteract threats such as infection and trauma. Such an inflammatory response begins with the detection of the potential life-threatening event by recognizing so-called danger signals. These signal molecules have been classically divided into: i) Exogenous, pathogen-associated molecular patterns (PAMPs) [1], which are conserved motifs on pathogens that are not found in higher eukaryocytes; and ii) endogenous innate danger molecules, also named damage-associated molecular patterns (DAMPs) or alarmins, which are structurally diverse proteins rapidly released by the host itself during infection or (sterile) tissue damage [2]. …
Literature
1.
Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20: 197-216. 10.1146/annurev.immunol.20.083001.084359CrossRefPubMed
2.
Bianchi ME: DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 2007, 81: 1-5. 10.1189/jlb.0306164CrossRefPubMed
3.
Harris HE, Raucci A: Alarmin(g) News about danger: Workshop on innate danger signals and HMGB1. EMBO Rep 2006, 7: 774-778.PubMedCentralPubMed
4.
Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418: 191-195. 10.1038/nature00858CrossRefPubMed
5.
Liu Y, Chen GY, Zheng P: CD24-Siglec G/10 discriminates danger-from pathogen-associated molecular patterns. Trends Immunol 2009, 30: 557-561. 10.1016/j.it.2009.09.006PubMedCentralCrossRefPubMed
6.
Liu R, Mori S, Wake H, et al.: Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin's effect on binding. Acta Med Okayama 2009, 63: 203-211.PubMed
7.
Bierhaus A, Stern DM, Nawroth PP: RAGE in inflammation: a new therapeutic Target? Curr Opin Investig Drugs 2006, 7: 985-991.PubMed
8.
Chavakis T, Bierhaus A, Al Fakhri N, et al.: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003, 198: 1507-1515. 10.1084/jem.20030800PubMedCentralCrossRefPubMed
9.
Liliensiek B, Weigand MA, Bierhaus A, et al.: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004, 113: 1641-1650.PubMedCentralCrossRefPubMed
10.
Goova MT, Li J, Kislinger T, et al.: Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001, 159: 513-525. 10.1016/S0002-9440(10)61723-3PubMedCentralCrossRefPubMed
11.
Cataldegirmen G, Zeng S, Feirt N, et al.: RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 2005, 201: 473-484. 10.1084/jem.20040934PubMedCentralCrossRefPubMed
12.
Park L, Raman KG, Lee KJ, et al.: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998, 4: 1025-1031. 10.1038/2012CrossRefPubMed
13.
Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108: 949-955.PubMedCentralCrossRefPubMed
14.
Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5: 331-342. 10.1038/nri1594CrossRefPubMed
15.
Ueno H, Matsuda T, Hashimoto S, et al.: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004, 170: 1310-1316. 10.1164/rccm.200402-188OCCrossRefPubMed
16.
Wang H, Bloom O, Zhang M, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285: 248-251. 10.1126/science.285.5425.248CrossRefPubMed
17.
van Zoelen MA, Laterre PF, van Veen SQ, et al.: Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 2007, 35: 2799-2804. 10.1097/01.CCM.0000287588.69000.97CrossRefPubMed
18.
Yang H, Ochani M, Li J, et al.: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004, 101: 296-301. 10.1073/pnas.2434651100PubMedCentralCrossRefPubMed
19.
20.
Suda K, Kitagawa Y, Ozawa S, et al.: Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 2006, 30: 1755-1762. 10.1007/s00268-005-0369-2CrossRefPubMed
21.
Wang H, Liao H, Ochani M, et al.: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004, 10: 1216-1221. 10.1038/nm1124CrossRefPubMed
22.
Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6: 813-822. 10.1038/nri1943CrossRefPubMed
23.
Hotchkiss RS, Chang KC, Swanson PE, et al.: Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000, 1: 496-501. 10.1038/82741CrossRefPubMed
24.
Tian J, Avalos AM, Mao SY, et al.: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8: 487-496. 10.1038/ni1457CrossRefPubMed
25.
Yang H, Hreggvidsdottir HS, Palmblad K, et al.: A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010, 107: 11942-11947. 10.1073/pnas.1003893107PubMedCentralCrossRefPubMed
26.
Wittkowski H, Sturrock A, van Zoelen MA, et al.: Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 2007, 35: 1369-1375. 10.1097/01.CCM.0000262386.32287.29CrossRefPubMed
27.
Orlova VV, Choi EY, Xie C, et al.: A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007, 26: 1129-1139. 10.1038/sj.emboj.7601552PubMedCentralCrossRefPubMed
28.
Frommhold D, Kamphues A, Hepper I, et al.: RAGE and ICAM-1 Cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood 2010, 116: 841-849. 10.1182/blood-2009-09-244293CrossRefPubMed
29.
Uchida T, Shirasawa M, Ware LB, et al.: Receptor for advanced glycation end-products is a marker of type i cell injury in acute lung injury. Am J Respir Crit Care Med 2006, 173: 1008-1015. 10.1164/rccm.200509-1477OCPubMedCentralCrossRefPubMed
30.
Cheng C, Tsuneyama K, Kominami R, et al.: Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 2005, 18: 1385-1396. 10.1038/modpathol.3800450CrossRefPubMed
31.
Englert JM, Hanford LE, Kaminski N, et al.: A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008, 172: 583-591. 10.2353/ajpath.2008.070569PubMedCentralCrossRefPubMed
32.
Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M: The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 2006, 19: 1437-1445.PubMed
33.
Buckley ST, Ehrhardt C: The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol. 2010, 2010: 917108.
34.
Queisser MA, Kouri FM, Konigshoff M, et al.: Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am J Respir Cell Mol Biol 2008, 39: 337-345. 10.1165/rcmb.2007-0244OCCrossRefPubMed
35.
Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, Rieber EP: Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res 2006, 323: 475-488. 10.1007/s00441-005-0069-0CrossRefPubMed
36.
Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, Muller M: Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol 1998, 44: 1147-1157.PubMed
37.
He M, Kubo H, Ishizawa K, et al.: The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007, 293: L1427-L1436. 10.1152/ajplung.00075.2007CrossRefPubMed
38.
Reynolds PR, Schmitt RE, Kasteler SD, et al.: Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. Am J Respir Cell Mol Biol 2010, 42: 545-551. 10.1165/rcmb.2008-0265OCCrossRefPubMed
39.
van Zoelen MA, Schouten M, de Vos AF, et al.: The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 2009, 182: 4349-4356. 10.4049/jimmunol.0801199CrossRefPubMed
40.
van Zoelen MA, van der Sluijs KF, Achouiti A, et al.: Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 2009, 391: 265-273. 10.1016/j.virol.2009.05.032PubMedCentralCrossRefPubMed
41.
Lutterloh EC, Opal SM, Pittman DD, et al.: Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007, 11: R122. 10.1186/cc6184PubMedCentralCrossRefPubMed
42.
van Zoelen MA, Schmidt AM, Florquin S, et al.: Receptor for advanced glycation end products facilitates host defense during Escherichia coli-induced abdominal sepsis in mice. J Infect Dis 2009, 200: 765-773. 10.1086/604730CrossRefPubMed
43.
van Zoelen MA, Achouiti A, Schmidt AM, et al.: Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during escherichia coli peritonitis. Crit Care Med 2010, 38: 1414-1422. 10.1097/CCM.0b013e3181de18bcPubMedCentralCrossRefPubMed
44.
van Zoelen MA, Yang H, Florquin S, et al.: Role of Toll-Like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009, 31: 280-284. 10.1097/SHK.0b013e318186262dPubMedCentralCrossRefPubMed
45.
Park JS, Svetkauskaite D, He Q, et al.: Involvement of Toll-Like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279: 7370-7377. 10.1074/jbc.M306793200CrossRefPubMed
46.
Payen D, Lukaszewicz AC, Belikova I, et al.: Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 2008, 34: 1371-1376. 10.1007/s00134-008-1048-1CrossRefPubMed
47.
Foell D, Wittkowski H, Vogl T, Roth J: S100 Proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81: 28-37. 10.1189/jlb.0306170CrossRefPubMed
48.
Cole AM, Kim YH, Tahk S, et al.: Calcitermin, a novel antimicrobial peptide isolated from human airway secretions. FEBS Lett 2001, 504: 5-10. 10.1016/S0014-5793(01)02731-4CrossRefPubMed
49.
Bopp C, Hofer S, Weitz J, et al.: SRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008, 147: 79-83. 10.1016/j.jss.2007.07.014CrossRefPubMed
50.
Hudson BI, Harja E, Moser B, Schmidt AM: Soluble levels of receptor for advanced glycation endproducts (SRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 2005, 25: 879-882. 10.1161/01.ATV.0000164804.05324.8bCrossRefPubMed
Metadata
Title
The role of receptor for advanced glycation endproducts (RAGE) in infection
Authors
Marieke AD van Zoelen
Ahmed Achouiti
Tom van der Poll
Publication date
01-04-2011
Publisher
BioMed Central
Published in
Critical Care / Issue 2/2011
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc9990

Other articles of this Issue 2/2011

Critical Care 2/2011 Go to the issue

Research

Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy

Commentary

Assessment of fluid responsiveness during increased intra-abdominal pressure: keep the indices, but change the thresholds

Research

Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study

Letter

How did you sleep in the ICU?

Editorial

When pressure does not mean volume? Body mass index may account for the dissociation

Commentary

Of mice and men (and sheep, swine etc.): The intriguing hemodynamic and metabolic effects of hydrogen sulfide (H2S)